Systasy Bioscience announces non-exclusive licence agreement with Boehringer Ingelheim for splitSENSOR assays
Systasy Bioscience GmbH and Boehringer Ingelheim International GmbH entered a non-exclusive licence agreement for cell-based splitSENSOR assays providing Boehringer Ingelheim with the options to screen for selected target activities relevant to schizophrenia.
Systasy“s proprietary splitSENSOR assays are applied to assess activities and specificities of druggable targets, such as receptor tyrosine kinases and G protein-coupled receptors. Through providing a better understanding of compound-mediated actions on target activation and inhibition at early stages of each screening campaign, the drug development process will be substantially accelerated.
Boehringer Ingelheim aims at generating lead structures against novel targets for the treatment of schizophrenia. Schizophrenia is a chronic, severe and disabling mental disorder ranked among the 12 most debilitating diseases by the World Health Organization. It affects about 1 in 100 people worldwide, changing the way they behave, think and perceive the world. Although anti-psychotic medications and psychosocial interventions can effectively reduce symptoms and improve patients“ lives, there remains a strong need for new drugs truly addressing causative mechanisms and cognitive impairment. To generate medications for effective therapeutic interventions targeting negative and cognitive impairments, Boehringer Ingelheim acquired a non-exclusive splitSENSOR licence to screen compound libraries of any size for selected targets, which may have an impact on the etiology of schizophrenia.
Systasy, a growing start-up company founded 2012 in Munich, provides cost-effective and highly innovative solutions to address critical and unmet needs of the pharmaceutical industry. Systasy“s products and services are ranging from the analysis of cellular target activities and specificities up to the simultaneous analysis of multiple pathway in living cells, based on their proprietary splitSENSOR and EXTassay technologies. Systasy takes advantage of their EXTassay technology to deliver profile analyses for a multitude of simultaneously occurring cellular events to customers. Thus, Systasy“s services and products are designed to match customers“ needs in the early phases of drug discovery and personalized medicine.
For further information, please visit: www.systasy.com
Firmenkontakt
Systasy Bioscience GmbH
Sven Wichert
Adams-Lehmann-Str. 56
80797 München
+49 (0) 89 2155 3085
wichert@systasy.de
Pressekontakt
Systasy Bioscience GmbH
Michael Wehr
Adams-Lehmann-Str. 56
80797 München
+49 (0) 89 2155 3085
wehr@systasy.de
